Application of combination of levocarnitine and L-arginine in preparation of drugs for treatment of diabetic retinopathy nerve damage

A technology for diabetic retina and nerve damage, which can be used in drug combinations, neurological diseases, sensory diseases, etc., and can solve problems such as treatment effectiveness and long-term safety.

Inactive Publication Date: 2014-07-30
HOSPITAL ATTACHED TO QINGDAO UNIV
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, currently commonly used drugs such as anti-vascular endothelial growth factor and gluco

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of levocarnitine and L-arginine in preparation of drugs for treatment of diabetic retinopathy nerve damage
  • Application of combination of levocarnitine and L-arginine in preparation of drugs for treatment of diabetic retinopathy nerve damage

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0021] 1.1 Experimental animals

[0022] Standard normal-grade SD rats born 1-3 days old were selected, provided by the Experimental Animal Center of Shandong Lukang Pharmaceutical Co., Ltd., in line with the national standards for the use of medical animals, and the standard number is clean grade.

[0023]1.2 The primary culture of SD rat retinal nerve cells and the establishment of high-glucose model include the following steps (see "Protective effect and mechanism of levocarnitine on high-glucose cultured rat retinal nerve cells in vitro", Chen Jie, Qingdao University Master Thesis, 2013):

[0024] 1.2.1 Preparation of the following main reagents

[0025] Containing 10% fetal bovine serum culture medium, glucose, 5-bromo-2' deoxyuridine, 4% paraformaldehyde, PBS phosphate buffer saline.

[0026] 1.2.2 Polylysine treatment of cell culture flasks or culture plates

[0027] In order to promote the attachment of the cultured retinal nerve cells, the cell culture flask or cul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a pharmaceutical composition containing L-arginine and levocarnitine in combined preparation of drugs for treatment of diabetic retinopathy nerve damage, and particularly relates to application of the pharmaceutical composition in preparation of the drugs for treatment of retinal nerve damage and Muller cell injury of diabetic retinopathy nerve damage. Cell and animal experiments show that compared with the single use of the levocarnitine, the diabetic retinopathy nerve damage and particularly the retinal nerve damage and Muller cell injury of diabetic retinopathy nerve damage can be more effectively protected by combination of the levocarnitine and the L-arginine, and the technical effect of synergistic interaction can be achieved.

Description

technical field [0001] The invention relates to the application of levocarnitine combined with L-arginine in the preparation of a drug for treating nerve damage caused by diabetic retinopathy. Background technique [0002] With the general improvement of human living standards and the extension of life expectancy, the incidence of diabetes at home and abroad is significantly higher than before. Diabetes has many complications, among which diabetic retinopathy (DR) is one of the most common and serious microvascular complications in the eye, and one of the main blinding eye diseases, mainly due to retinal microvascular lesions As a result, a series of pathological changes in the retina are caused, and the incidence and severity increase with the prolongation of the duration of diabetes. Studies have reported that if the duration of diabetes is as long as 5 years, the incidence of DR can reach 44.4%, and if the duration of diabetes is 7 years, the incidence of DR can be as hi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/205A61P25/02A61P27/02A61K31/198
Inventor 曹玉王云霄赵振寰王兰凤耿清波
Owner HOSPITAL ATTACHED TO QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap